Maximising the cost-effectiveness of human papillomavirus testing for cervical screening in the context of routine HPV vaccination in Hong Kong: abridged secondary publication
SMK Leung1, J Wu1, KKL Chan2, M Jit3
1 School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
2 Department of Obstetrics and Gynaecology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
3 Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK
- Among cohorts without a human papillomavirus (HPV) vaccination programme, use of the HPV test as a standalone primary test or as a screening test after receiving cytological analysis of atypical squamous cells of undetermined significance was considered a cost-effective cervical screening strategy to reduce deaths from cervical cancer when the willingness-to-pay threshold was one gross domestic product per capita (US$46 615).
- Reassessment of the comparative cost-effectiveness of strategies with longer routine screening intervals, a pre-defined fixed number of routine screenings per lifetime, or a later starting age is needed to identify optimal screening strategies for vaccinated cohorts, especially when newer data about the duration of vaccine protection become available.